Filter Publications
Publications
| # | Title | Products | Kits | Action |
|---|---|---|---|---|
| Peña-Cabia, Silvia, et al. "Assessment of exposure-response relationship for cetuximab in patients with metastatic colorectal cancer and head and neck cancer." Farmacia Hospitalaria: Organo Oficial de Expresion Cientifica de la Sociedad Espanola de Farmacia Hospitalaria 46.1 (2021): 21-26. Pharmacy Unit, Severo Ochoa University Hospital, Madrid, Spain |
CETUXIMAB |
Shikari® (Q-CET) Cetuximab ELISA |
Visit Link | |
| Guven, Deniz Can, et al. "Immunogenicity of two doses of inactive COVID‐19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy." International Journal of Cancer (2022). Hacettepe University Cancer Institute, Department of Medical Oncology, Ankara, Turkey. |
CORONAHUNTER® ELISA KITS |
CORONAHUNTER® (Q-CORSRBD) anti-spike RBD IgG ELISA |
Visit Link | |
| Liu, Zheng, et al. "Timing of live attenuated vaccination in infants exposed to infliximab or adalimumab in utero: A prospective cohort study in 107 children." Journal of Crohn's and Colitis (2022). Clinical Pharmacology, School of Medicine and Public Health, University of Newcastle, Hunter Medical Research Institute, Kookaburra Circuit, Australia. |
INFLIXIMAB ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Kita, Toshihiro, et al. "Adrenomedullin for biologic‐resistant Crohn's disease: A randomized, double‐blind, placebo‐controlled phase 2a clinical trial." Journal of Gastroenterology and Hepatology (2022). Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki |
INFLIXIMAB ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Iwasaki, Takeshi, et al. "Dynamics of type I and type II interferon signature determines responsiveness to anti-TNF therapy in rheumatoid arthritis." Frontiers in immunology 13 (2022). Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan. |
INFLIXIMAB ADALIMUMAB ETANERCEPT |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (S-ATA) Anti-Adalimumab ELISA w/confirmation Shikari® (Q-ETA) Etanercept ELISA Shikari® (S-ATE) Anti-Etanercept ELISA Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Cantarelli, Lorenzo, et al. "Definition of a therapeutic range for predicting long-term infliximab response in patients with inflammatory bowel disease." Medicina Clínica (2022). Servicio de Farmacia. Complejo Hospitalario Universitario de Canarias, Tenerife, Spain. |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Kawamoto, Ami, et al. "Serum Levels of Infliximab Biosimilar in a Child Delivered From a Mother Treated for Ulcerative Colitis." Inflammatory Bowel Diseases 28.8 (2022): 1298-1299. Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan. |
INFLIXIMAB |
Shikari® (Q-REMS) Infliximab biosimilar ELISA |
Visit Link | |
| Sinha, Aditi, et al. "Sequential rituximab therapy sustains remission of nephrotic syndrome, but carries high risk of adverse effects." Nephrology Dialysis Transplantation (2022). Division of Nephrology and ICMR Center for Advanced Research in Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India. |
RITUXIMAB |
Shikari® (Q-RITUX) Rituximab ELISA |
Visit Link | |
| Chen, Yewei, et al. "Population Pharmacokinetics of Rituximab in Pediatric Patients With Frequent-Relapsing or Steroid-Dependent Nephrotic Syndrome." Frontiers in Pharmacology (2021): 2348. Department of Pharmacy, Children’s Hospital of Fudan University, Shanghai, China |
RITUXIMAB |
Shikari® (Q-RITUX) Rituximab ELISA |
Visit Link | |
| Linares, Raquel, et al. "Transcriptional regulation of chemokine network by biologic monotherapy in ileum of patients with Crohn’s disease." Biomedicine & Pharmacotherapy 147 (2022): 112653. Hepatic and Intestinal Immunobiology Group, Departamento Medicina Clínica, Universidad Miguel Hernandez, Spain |
ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA |
Visit Link | |
| Kim, Eun Sil, et al. "Albumin-to-Globulin Ratio at 1 Year after Anti-Tumor Necrosis Factor α Therapy Can Serve as a Prognostic Biomarker in Pediatric Crohn’s Disease Patients." Gut and Liver 16.1 (2022): 71. Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea |
ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA |
Visit Link | |
| Orts, Beatriz, et al. "Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn's Disease." Frontiers in pharmacology 12 (2021): 795272-795272. Unidad de Farmacología Clínica, Hospital General Universitario de Alicante, Alicante, Spain |
INFLIXIMAB ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (S-ATA) Anti-Adalimumab ELISA w/confirmation Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Pękala, Anna, and Rafał Filip. "Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn’s Disease and Ulcerative Colitis— A Prospective Polish Population Study." Journal of Clinical Medicine 10.22 (2021): 5311. Department of Gastroenterology with IBD, Unit of Clinical Hospital 2 in Rzeszow, Rzeszow, Poland |
INFLIXIMAB-BIOSIMILAR |
Shikari® (Q-REMS) Infliximab biosimilar ELISA |
Visit Link | |
| MOHSEN, ENAS RIYADH, and NAAEL H. ALI. "IMPACT OF TH17/TREGFOXP3 CELLS RATIO ON RHEUMATOID ARTHRITIS PATIENTS RECEIVING ANTI TNF-THERAPY-." Journal of Duhok University 24.2 (2021): 90-102.APA College of Medicine, University of Basrah-Iraq |
INFLIXIMAB ETANERCEPT |
Shikari® (S-ATE) Anti-Etanercept ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| De Gregorio, Michael, et al. "Higher Anti-tumor Necrosis Factor-α Levels Correlate With Improved Radiologic Outcomes in Crohn’s Perianal Fistulas." Clinical Gastroenterology and Hepatology (2021). St Vincent’s Hospital Melbourne, Department of Gastroenterology, Fitzroy, Australia |
ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA |
Visit Link | |
| Нуриахметова, Т. Ю., et al. "Особенности ответа на инфликсимаб пациентов с воспалительными заболеваниями кишечника и анкилозирующим спондилитом." Русский медицинский журнал. Медицинское обозрение 5.2 (2021): 64-70. FSBEI HE Kazan State Medical University of the Ministry of Health of Russia, Kazan, Russia |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| Liu, Shu, et al. "Rituximab exposure‐response in triweekly R‐CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes." Clinical and Translational Science (2021). State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China |
RITUXIMAB |
Shikari® (Q-RITUX) Rituximab ELISA |
Visit Link | |
| Patil, A., Upadhyaya, S., Dawar, R., Dadhaniya, N., Sood, I., Gupta, S. J., Handa, R. Anti-drug antibodies and low serum trough infliximab levels correlate with disease activity measures in spondyloarthritis patients on an as-needed infliximab treatment. International Journal of Rheumatic Diseases (2019) Department of Rheumatology, Indraprastha Apollo Hospitals, Delhi, India |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| Yang Wu, et al., Management Decisions in Crohn’s Disease Are Changed by Knowledge of Proactive and Reactive Testing of Antitumor Necrosis Factor Drug Levels, Crohn's & Colitis 360, Volume 3, Issue 3, (2021) Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, New South Wales, Australia |
INFLIXIMAB ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (S-ATA) Anti-Adalimumab ELISA w/confirmation Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Tae Jong Jeong, Eun Sil Kim et al. Discontinuation of Azathioprine Could Be Considered in Pediatric Patients with Crohn’s Disease who Have Sustained Clinical and Deep Remission, Scientific Reports (2021) Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Pękala, Anna, and Rafał Filip. "Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study" Journal of Clinical Medicine (2021) Department of Gastroenterology with IBD, Unit of Clinical Hospital 2 in Rzeszow, Rzeszow, Poland |
INFLIXIMAB-BIOSIMILAR ADALIMUMAB |
Shikari® (Q-REMS) Infliximab biosimilar ELISA Shikari® (Q-ADA) Adalimumab ELISA |
Visit Link | |
| Alañón Pardo, M. M., et al. "Monitorización farmacocinética de terapias biológicas en enfermedad inflamatoria intestinal." Revista de la OFIL 31.1 (2021): 49-57. Hospital General La Mancha – Centro (Alcázar de San Juan). Ciudad Real, Spain |
INFLIXIMAB ADALIMUMAB |
Shikari® (S-ATA) Anti-Adalimumab ELISA w/confirmation Shikari® (S-ATA) Anti-Adalimumab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| Little, Robert D., et al. "De-escalation from Dose-Intensified Anti-TNF Therapy Is Successful in the Majority of IBD Patients at 12 Months." Digestive Diseases and Sciences (2021): 1-4. Department of Gastroenterology, Alfred Health and Monash University, Melbourne 3004, Australia |
INFLIXIMAB ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Kim, Mi Jin, et al. "Therapeutic Drug Monitoring of Adalimumab During Long-term Follow-up in Paediatric Patients With Crohn Disease." Journal of Pediatric Gastroenterology and Nutrition 72.6 (2021): 870-876. Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul. |
ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA |
Visit Link | |
| Ward, Mark G., et al. "Comparison of Sb2-Infliximab with Originator-Infliximab in the Measurement of Serum Concentrations A Short Communication." Therapeutic Drug Monitoring (2021). Department of Gastroenterology, Alfred Hospital and Monash University, Melbourne, Victoria |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Mocenigo, Marco, et al. "Rapid, Cost-Effective Peptide/Nucleic Acid-Based Platform for Therapeutic Antibody Monitoring in Clinical Samples." ACS sensors 5.10 (2020): 3109-3115. Ulisse BioMed Labs, Area Science Park, SS 14, km 163.5, 34149 Trieste, Italy Molecular Genetics and Biotechnology PhD study programme, University of Nova Gorica, Vipavska 13, Nova Gorica, Slovenia |
TRASTUZUMAB |
Shikari® (Q-TRAS) Trastuzumab ELISA |
Visit Link | |
| Judit Szántó, Kata, et al. "Advances in the optimisation of therapeutic drug monitoring using serum, tissue and faecal anti-tumour necrosis factor concentration in patients with inflammatory bowel disease treated with TNF-α antagonists." Expert Opinion on Biological Therapy (2021). Department of Medicine, of Szeged, Szeged, Hungary. |
INFLIXIMAB ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (S-ATA) Anti-Adalimumab ELISA w/confirmation Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Esatoglu, Sinem Nihal, et al. "Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled Study." Frontiers in Immunology 11 (2020): 3378. Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Padrón, Ivette Mourani, et al. "Anti-drug antibodies anti-trastuzumab in the treatment of breast cancer." Journal of Oncology Pharmacy Practice (2020): 1078155220953873. Fundación Canaria Instituto de Investigación Sanitaria de Canarias, Complejo Hospitalario Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain. |
TRASTUZUMAB |
Shikari® (S-ATT) Anti-Trastuzumab ELISA |
Visit Link | |
| Luber, Raphael P., et al. "Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease." Journal of Gastroenterology and Hepatology (2020). Department of Gastroenterology, Alfred Hospital, Department of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Formica, María Lina, et al. "Novel hybrid lipid nanocapsules loaded with a therapeutic monoclonal antibody–Bevacizumab–and Triamcinolone acetonide for combined therapy in neovascular ocular pathologies." Materials Science and Engineering: C 119 (2020): 111398. Departamento de Farmacia, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Ciudad Universitaria, 5000 Córdoba, Argentina. |
BEVACIZUMAB |
Shikari® (Q-BEVA) Bevacizumab ELISA |
Visit Link | |
| Zhang, Jinhua, et al. "sRNA-based screening chromosomal gene targets and modular designing Escherichia coli for high-titer production of aglycosylated immunoglobulin G." ACS Synthetic Biology (2020). Frontier Science Center for Synthetic Biology, Key Laboratory of Systems Bioengineering (MOE), Collaborative Innovation Centre of Chemical Science and Engineering (Tianjin), and School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, P. R. China |
CETUXIMAB |
Shikari® (Q-CET) Cetuximab ELISA |
Visit Link | |
| Yokoyama, Yoko, et al. "Efficacy of Granulocyte and Monocyte Adsorptive Apheresis in Patients with Inflammatory Bowel Disease Showing Lost Response to Infliximab." Journal of Crohn's and Colitis (2020). Division of Internal Medicine, Department of Inflammatory Bowel Disease, Hyogo College of Medicine, Hyogo, Japan. |
INFLIXIMAB |
Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Sureda, Manuel, et al. "Therapeutic drug monitoring of nivolumab in routine clinical practice. A pilot study." Farmacia Hospitalaria: Organo Oficial de Expresion Cientifica de la Sociedad Espanola de Farmacia Hospitalaria 44.3 (2020): 81-86. Plataforma de Oncología, Hospital Quironsalud Torrevieja, Torrevieja (Alicante). Spain. |
NIVOLUMAB |
Shikari® (Q-NIVO) Nivolumab ELISA |
Visit Link | |
| Seong, Gyeol, et al. "Changes in the Intestinal Microbiota of Patients with Inflammatory Bowel Disease with Clinical Remission during an 8-Week Infliximab Infusion Cycle." Microorganisms 8.6 (2020): 874. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Nieto, Juan C., et al. "Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy." Leukemia (2020): 1-6. Laboratory of Experimental Hematology, Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital (HUVH), Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain. |
NIVOLUMAB |
Shikari® (Q-NIVO) Nivolumab ELISA |
Visit Link | |
| Liu, Shu, et al. "Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2." Acta Pharmacologica Sinica (2020): 1-7. Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China. |
RITUXIMAB |
Shikari® (Q-RITUX) Rituximab ELISA |
Visit Link | |
| Choi, So Yoon, et al. "Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients." Journal of Korean Medical Science 35.16 (2020). Department of Pediatrics, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea |
ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (S-ATA) Anti-Adalimumab ELISA |
Visit Link | |
| González García, Jonathan, et al. "Pharmacokinetics of Trastuzumab After Subcutaneous and Intravenous Administration in Obese Patients." Annals of Pharmacotherapy (2020): 1060028020902318. Complejo Hospitalario Universitario de Canarias, Santa Cruz de Tenerife, La Laguna, Spain. |
TRASTUZUMAB |
Shikari® (Q-TRAS) Trastuzumab ELISA |
Visit Link | |
| de Redín, Inés Luis, et al. "In vivo efficacy of bevacizumab-loaded albumin in the treatment of colorectal cancer." Drug Delivery and Translational Research (2020): 1-11. Department of Chemistry and Pharmaceutical Technology, NANO-VAC Research Group, University of Navarra, Pamplona, Spain. |
BEVACIZUMAB |
Shikari® (Q-BEVA) Bevacizumab ELISA |
Visit Link | |
| Abe, Kazuki, et al. "Quantitative LC-MS/MS method for nivolumab in human serum using IgG purification and immobilized tryptic digestion." Analytical Methods 12.1 (2020): 54-62. Department of Hospital Pharmacy, Hamamatsu University School of Medicine,1-20-1 Handayama, Higashi-ku, Hamamatsu 431-3192, Japan |
NIVOLUMAB |
Shikari® (Q-NIVO) Nivolumab ELISA |
Visit Link | |
| Zhang, Jinhua, et al. "Synthetic sRNA‐based Engineering of Escherichia coli for Enhanced Production of Full‐length Immunoglobulin G." Biotechnology Journal (2020): 1900363. Frontier Science Center for Synthetic Biology and Key Laboratory of Systems Bioengineering (MOE), School of Chemical Engineering and Technology Tianjin University, Tianjin 300350, P. R. China |
CETUXIMAB |
Shikari® (Q-CET) Cetuximab ELISA |
Visit Link | |
| Flanagan, E., et al. "Stability of serum concentrations of infliximab and adalimumab across pregnancy in IBD." JOURNAL OF CROHNS & COLITIS. Vol. 13. GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND: OXFORD UNIV PRESS, 2019. St Vincent's Hospital, Gastroenterology, Melbourne, Australia |
INFLIXIMAB ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Puente‐Massaguer, Eduard, et al. "A statistical approach to improve compound screening in cell culture media." Engineering in Life Sciences 19.4 (2019): 315-327. Departament d'Enginyeria Química, Biològica i Ambiental, Campus Bellaterra, Cerdanyola del Vallès, Universitat Autònoma de Barcelona, Barcelona, Spain |
TRASTUZUMAB |
Shikari® (Q-TRAS) Trastuzumab ELISA |
Visit Link | |
| Choi, So Yoon, Ben Kang, and Yon Ho Choe. "Serum Infliximab Cutoff Trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease." Gut and liver (2019). Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| González-García, J., et al. "Long-term stability of trastuzumab in plasma and whole blood samples stored under different conditions." Farmacia hospitalaria: organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 43.2 (2019): 50-52. Servicio de Farmacia, Complejo Hospitalario Universitario de Canarias, San Cristóbal de La Laguna, Tenerife. Spain |
TRASTUZUMAB |
Shikari® (Q-TRAS) Trastuzumab ELISA |
Visit Link | |
| Llabot, Juan M., et al. "In vitro characterization of new stabilizing albumin nanoparticles as a potential topical drug delivery system in the treatment of corneal neovascularization (CNV)." Journal of Drug Delivery Science and Technology 52 (2019): 379-385. UNITEFA – CONICET, Facultad de Ciencias Químicas (FCQ-UNC). Córdoba, Argentina |
BEVACIZUMAB |
Shikari® (Q-BEVA) Bevacizumab ELISA |
Visit Link | |
| Sureda, Manuel, et al. "Therapeutic drug monitoring of nivolumab in clinical practice: Preliminary experience." DEVELOPMENTAL IMMUNOTHERAPY AND TUMOR IMMUNOBIOLOGY (2019) Plataforma de Oncologia, Hospital Quironsalud Torrevieja. Catedra Oncologia Multidisciplinar-UCAM, Torrevieja, Spain |
NIVOLUMAB |
Shikari® (Q-NIVO) Nivolumab ELISA |
Visit Link | |
| Zapater, Pedro, et al. "Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn’s Disease." Inflammatory bowel diseases (2019). Servicio de Farmacología Clínica, Hospital General Universitario de Alicante, Alicante, Spain. |
INFLIXIMAB ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (S-ATA) Anti-Adalimumab ELISA Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| Vasudevan, Abhinav, et al. "Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn’s Disease." Digestive diseases and sciences (2018): 1-10. Department of Gastroenterology and Hepatology, Eastern Health, Box Hill Hospital, Australia |
INFLIXIMAB ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Kang, Ben, et al. "Infliximab Trough Levels Are Associated With Mucosal Healing During Maintenance Treatment With Infliximab in Paediatric Crohn’s Disease." Journal of Crohn's and Colitis (2018). Department of Pediatrics, School of Medicine, Kyungpook National University, Daegu, South Korea |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Bálint, Anita, et al. "Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis–results from multicentre observational cohort." Expert opinion on biological therapy just-accepted (2018). Department of Medicine , University of Szeged , Szeged , Hungary. |
INFLIXIMAB |
Shikari® (Q-REMS) Infliximab biosimilar ELISA |
Visit Link | |
| González García, Jonathan, et al. "Influence of anthropometric characteristics in patients with Her2-positive breast cancer on initial plasma concentrations of trastuzumab." Annals of Pharmacotherapy 51.11 (2017): 976-980. Complejo Hospitalario Universitario de Canarias (Santa Cruz de Tenerife), La Laguna, Spain |
TRASTUZUMAB |
Shikari® (Q-TRAS) Trastuzumab ELISA |
Visit Link | |
| Kang, Ben, et al. "Long-term Outcomes After Switching to CT-P13 in Pediatric-Onset Inflammatory Bowel Disease: A Single-Center Prospective Observational Study." Inflammatory bowel diseases 24.3 (2018): 607-616. Department of Pediatrics, Kyungpook National University School of Medicine, Daegu, Republic of Korea |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Duricova, Dana, et al. "Safety of Anti-TNF-Alpha Therapy During Pregnancy on Long-term Outcome of Exposed Children: A Controlled, Multicenter Observation." Inflammatory bowel diseases (2018). IBD Clinical and Research Center, ISCARE IVF, a.s., Prague, Czech Republic |
INFLIXIMAB ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Gregoritza, Manuel, et al. "Fabrication of antibody-loaded microgels using microfluidics and thiol-ene photoclick chemistry." European Journal of Pharmaceutics and Biopharmaceutics 127 (2018): 194-203. Department of Pharmaceutical Technology, Faculty of Chemistry and Pharmacy, University of Regensburg, 93040 Regensburg, Germany. |
BEVACIZUMAB |
Shikari® (Q-BEVA) Bevacizumab ELISA |
Visit Link | |
| de Redín, Inés Luis, et al. "Human serum albumin nanoparticles for ocular delivery of bevacizumab." International journal of pharmaceutics 541.1-2 (2018): 214-223. Department of Pharmacy and Pharmaceutical Technology, NANO-VAC Research Group, University of Navarra, Spain |
BEVACIZUMAB |
Shikari® (Q-BEVA) Bevacizumab ELISA |
Visit Link | |
| Pérez, Irene, et al. "Reliability evaluation of four different assays for therapeutic drug monitoring of infliximab levels." Therapeutic Advances in Gastroenterology 11 (2018): 1756284818783613. Inflammatory Bowel Disease Unit, Department of Gastroenterology, Hospital Clínico San Carlos, Madrid, Spain |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| Bolia, Rishi, et al. "Secondary Loss of Response to Infliximab in Pediatric Crohn Disease: Does It Matter How and When We Start?." Journal of pediatric gastroenterology and nutrition 66.4 (2018): 637-640. Department of Gastroenterology Royal Children's Hospital Melbourne Parkville, Avustralya |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Kang, Ben, et al. "Subtherapeutic infliximab trough levels and complete mucosal healing are associated with sustained clinical remission after infliximab cessation in paediatric-onset Crohn’s disease patients treated with combined immunosuppressive therapy." Journal of Crohn's and Colitis 12.6 (2018): 644-652. Department of Pediatrics, Kyungpook National University School of Medicine, Daegu, Korea |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| Shirai, Shimpei, et al. "Immunogenicity of Quadrivalent Influenza Vaccine for Patients with Inflammatory Bowel Disease Undergoing Immunosuppressive Therapy." Inflammatory bowel diseases 24.5 (2018): 1082-1091. Departments of Internal Medicine and Gastrointestinal Endoscopy, Faculty of Medicine, Saga University, Saga City, Saga, Japan. |
ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA |
Visit Link | |
| Iwamoto, Noriko, Akinobu Hamada, and Takashi Shimada. "Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis." Analytical biochemistry 540 (2018): 30-37. Leading Technology of Bioanalysis and Protein Chemistry, SHIMADZU Corporation, Kuwabara-cho, Nishino-kyo, Nakagyo-ku, Kyoto 604-8511, Japan |
TRASTUZUMAB |
Shikari® (Q-TRAS) Trastuzumab ELISA |
Visit Link | |
| Sugita, Naoko, et al. "Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease." Journal of gastroenterology and hepatology 33.3 (2018): 631-637. Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan. |
ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA |
Visit Link | |
| M. Kolar et al., "Pregnancy outcomes in women with inflammatory bowel disease treated with biosimilar infliximab" Gastroent Hepatol (2018) 72(1): 20-26 IBD Clinical and Research Centre, Prague,Czech Republic |
INFLIXIMAB |
Shikari® (Q-REMS) Infliximab biosimilar ELISA |
Visit Link | |
| Jing Chen et. al., "Tailor-Making Fluorescent Hyaluronic Acid Microgels via Combining Microfluidics and Photoclick Chemistry for Sustained and Localized Delivery of Herceptin in Tumor." ACS Appl. Mater. Interfaces, (2018). Biomedical Polymers Laboratory, and Jiangsu Key Laboratory of Advanced Functional Polymer Design and Application, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, People’s Republic of China |
TRASTUZUMAB |
Shikari® (Q-TRAS) Trastuzumab ELISA |
Visit Link | |
| Beswick, Lauren, et al. "Exploration of predictive biomarkers of early infliximab response in acute severe colitis: A prospective pilot study." Journal of Crohn's and Colitis 12.3 (2017): 289-297. Department of Gastroenterology, Alfred Health and Monash University, Melbourne, Australia |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Piñero, Paula, et al. "IL26 modulates cytokine response and anti-TNF consumption in Crohn’s disease patients with bacterial DNA." Journal of Molecular Medicine 95.11 (2017): 1227-1236. CIBERehd, Instituto de Salud Carlos III, Madrid, Spain. |
INFLIXIMAB ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Štefan Raffáč et al., "Detection of anti-infliximab antibodies in Slovak IBD patients and its costs saving effect" Neuroendocrinology Letters Volume 38 Suppl. 1 (2017) Department of laboratory medicine, Louis Pasteur University Hospital, Košice, Slovakia |
INFLIXIMAB |
Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Ward, M. G., et al. "Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease." Alimentary pharmacology & therapeutics 45.8 (2017): 1135-1145. Department of Gastroenterology, Alfred Hospital, Melbourne, Vic., Australia. |
ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA |
Visit Link | |
| Kevin H, et al, “Prolonged in vivo expression and anti-tumor response of DNA-based anti-HER2 antibodies”: Oncotarget, 2018, Vol. 9, (No. 17), pp: 13623-13636. Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven – University of Leuven, Leuven B-3000, Belgium |
TRASTUZUMAB |
Shikari® (Q-TRAS) Trastuzumab ELISA |
Visit Link | |
| Aomori, Tohru, et al. "Suppression of infliximab antibody levels by azathioprine in patients with rheumatoid arthritis." Die Pharmazie-An International Journal of Pharmaceutical Sciences 72.2 (2017): 95-97. Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8521, Japan |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Kaito Shibata, et al. Simple and rapid LC-MS/MS method for the absolute determination of cetuximab in human serum using an immobilized trypsin Journal of Pharmaceutical and Biomedical Analysis Volume 146, Pages 266-272, 30 November 2017 Department of Hospital Pharmacy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan |
CETUXIMAB |
Shikari® (Q-CET) Cetuximab ELISA |
Visit Link | |
| Johannes Gojo, Robert Sauermann, Ursula Knaack, Irene Slave, Andreas Peyrl, Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3 Years with CNS Malignancies. Drugs R D 17:469-474, 2017. Department of Pediatrics, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria |
BEVACIZUMAB |
Shikari® (Q-BEVA) Bevacizumab ELISA |
Visit Link | |
| Ohem J, Hradsky O, Zarubova K, Copova I, Bukovska P, Prusa R, Malickova K and Bronsky J. Evaluation of Infliximab Therapy in Children with Crohn's Disease Using Trough Levels Predictors. Dig Dis. Aug 18, 2017. Gastroenterology and Nutrition Unit, Department of Paediatrics, Prague, Czech Republic |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Al-Karkhi MA, Al-Ani MM, Jassim NA, Mahdi BM, Association Between HLA-DRB1 alleles and development of antibodies to infliximab in Iraqi patients with rheumatoid arthritis, Basic Research Journals, 6(3): 30-35, 2017. Department of Microbiology and Immunology, Baquba Teaching Hospital. |
INFLIXIMAB |
Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Bálint A, Rutka M, Végh Z, et al. Frequency and Characteristics of Infusion Reactions during Biosimilar Infliximab Treatment in Inflammatory Bowel Diseases: results from Central European nationwide cohort, Expert Opinion on Drug Safety, 16(8):885-890, 2017. First Department of Medicine, University of Szeged, Szeged, Hungary; |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| Lombardi S, Bernardoni C, Bertolucci D, et al. Biologic therapies in rheumatic diseases: drug and anti-drug antibody levels and clinical efficacy. Journal of Autoimmunity and Cell Responses, 4(1), 2017. SSD Clinical Analysis and Immunoallergology, Massa Carrara, Italy |
ETANERCEPT |
Shikari® (Q-ETA) Etanercept ELISA |
Visit Link | |
| Gregoritza M, Messmann V, Abstiens K, Brandl FP, Göpferich AM, Controlled antibody release from degradable thermoresponsive hydrogels cross-linked by Diels-Alder chemistry, Biomacromolecules, Just Accepted Manuscript, 2017. Department of Pharmaceutical Technology, Faculty of Chemistry and Pharmacy, University of Regensburg, 93040 Regensburg, Germany |
BEVACIZUMAB |
Shikari® (Q-BEVA) Bevacizumab ELISA |
Visit Link | |
| Aldrich MB, Velasquez FC, Kwon S, Lymphatic delivery of etanercept via nanotopography improves response to collagen-induced arthritis, et al., Arthritis Research & Therapy 19:116, 2017. The Center for Molecular Imaging, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center, Houston, TX 77030, USA |
ETANERCEPT |
Shikari® (Q-ETA) Etanercept ELISA |
Visit Link | |
| Kolar M, Duricova D, Bortlik M, et al., Infliximab Biosimilar (Remsima TM ) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre, Digestive Disease, 35:91–100, 2017. a IBD Clinical and Research Centre, ISCARE, Prague, Czech Republic |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| Gibellini L, De Biasi S, Bianchini E, et al. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis. Richard Y, ed. PLoS ONE. 11(12), 2016 Department of Surgery, Medicine, Dentistry and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy |
INFLIXIMAB ADALIMUMAB ETANERCEPT |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (S-ATA) Anti-Adalimumab ELISA Shikari® (Q-ETA) Etanercept ELISA Shikari® (S-ATE) Anti-Etanercept ELISA Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| Julsgaard M, Christensen LA, Gibson PR, Bell SJ. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology. Jul;151(1):110-9, 2016. Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus C, Denmark. |
INFLIXIMAB ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Jonathan GG, Beatriz AÁ, Nazco C GJ, Norberto BL, Fernando GN. Plasma levels of trastuzumab in gastric cancer: Case report. J Oncol Pharm Pract. Sep 23, 2016. Pharmacy, Complejo Hospitalario Universitario de Canarias, San Cristo´bal de La Laguna, Santa Cruz de Tenerife, Spain |
TRASTUZUMAB |
Shikari® (Q-TRAS) Trastuzumab ELISA |
Visit Link | |
| Choi SY, Kang B, Lee JH, Choe YH. Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease. Gut Liver, 2016. Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Chen L., et al., Efficient Production of a Bioactive Bevacizumab Monoclonal Antibody Using the 2A Self-cleavage Peptide in Transgenic Rice Callus. Frontiers in Plant Science, 7 (1156), 2016. School of Life Sciences, Sun Yat-sen University, Guangzhou, China |
BEVACIZUMAB |
Shikari® (Q-BEVA) Bevacizumab ELISA |
Visit Link | |
| Kang B., et al., Mucosal Healing in Paediatric Patients with Moderate-to-Severe Luminal Crohn’s Disease Under Combined Immunosuppression: Escalation versus Early Treatment Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea |
INFLIXIMAB |
Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Farkas K., et al., Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis. Journal of Crohn's and Colitis Advance Access published, 2016. Department of Medicine, University of Szeged, Szeged, Hungary |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| Gutiérrez A, Zapater P, Francés R. Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients with Crohn's Disease. Am J Gastroenterol.,111(4):529-40, 2016. Servicio de Medicina Digestiva, Hospital General Universitario de Alicante, Alicante, Spain. |
INFLIXIMAB ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (S-ATA) Anti-Adalimumab ELISA Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| Won Jae Song, Ben Kang, So Yoon Choi, and Yon Ho Choe. Adalimumab Treatment in Pediatric-Onset Crohn’s Disease Patients after Infliximab Failure: A Single Center Study. Pediatr Gastroenterol Hepatol Nutr.; 19(2): 116–122, 2016. Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea |
INFLIXIMAB |
Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| Hayashi S, et al., Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate. Rheumatol Ther., 3:155–166, 2016. Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Kui R, Gál B, Gaál M, Kiss M, Kemény L1, Gyulai R. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis. J Dermatol.,43(9):1018-23, 2016. IBD Clinical and Research Centre, Iscare a.s., Prague, Czech Republic, |
INFLIXIMAB ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Al-Karkhi M.A., et al., Correlation between Anti-infliximab and Anti-CCP Antibodies Development in Patients with Rheumatoid Arthritis Treated with Infliximab in Baghdad Teaching Hospital. IOSR Journal of Dental and Medical Sciences, 14(11) : 95-100, 2015. Department of Microbiology & Immunology, College of medicine, University of Baghdad |
INFLIXIMAB |
Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| Bodini G., Edoardo G. Giannini, Edoardo V. Savarino, and Vincenzo Savarino. Adalimumab Trough Levels and Response to Biological Treatment in Patients With Infl ammatory Bowel Disease: A Useful Cutoff in Clinical Practice. Am J Gastroenterol., Vol.110, 2015. Gastroenterology Unit, Department of Internal Medicine, IRCCS-Azienda Ospedaliera Universitaria San Martino-IST, University of Genoa, Genoa, Italy. |
ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA |
Visit Link | |
| Juanola O., et al., Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn’s disease. J Gastroenterol,50:758–768, 2015. CIBERehd, Instituto de Salud Carlos III, Madrid, Spain. |
INFLIXIMAB ADALIMUMAB |
Shikari® (S-ATA) Anti-Adalimumab ELISA Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| Fujita T, Murata Y, Hemmi S, Kajiwara M, Yabuki M, et al. (2015) Persistent Complement Activation is Associated with Insulin Resistance and Chronic Inflammation in Overweight Patients with Type 2 Diabetes with Dyslipidemia. Int J Immunol Immunother 2:007, 2015. Department of Nephrology, Hypertension and Endocrinology, Nihon University School of Medicine, Japan |
SHIKARI® ELISA KITS |
Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Malíckova K, et al., Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease, Biologicals 2015. nstitute of Medical Biochemistry and Laboratory Diagnostics, 1st Medical Faculty and General Teaching Hospital, Charles University, Prague, Czech Republic. |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Lee Y.M. et al, Infliximab ‘‘Top-Down’’ Strategy is Superior to ‘‘Step-Up’’ in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease. JPGN 60: (737–743), 2015. Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Goyang, South Korea |
INFLIXIMAB |
Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Al-Karkhi M.A., et al., Development of Antibodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis. J Fac Med Baghdad, 57: (241-243), 2015 Dept. of Microbiology &Immunology, college of medicine, University of Baghdad |
INFLIXIMAB |
Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| Bergen T.V., et al., Complementary effects of bevacizumab and MMC in the improvement of surgical outcome after glaucoma filtration surgery. Acta Ophthalmologica, 667-678, 2015. Laboratory of Ophthalmology, KU Leuven, Leuven, Belgium |
BEVACIZUMAB |
Shikari® (Q-BEVA) Bevacizumab ELISA |
Visit Link | |
| Aydın C, Ataoğlu H., Demonstration of β-1,2 Mannan Structures Expressed on the Cell Wall of Candida albicans Yeast Form But Not on the Hyphal Form by Using Monoclonal Antibodies Mikrobiyol Bul 49(1): 66-76, 2015. Ankara University Biotechnology Institute, Ankara, Türkiye |
SHIKARI® ELISA KITS |
Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Kozub P, Curkova AK, Zuzulova M, Simaljakova M, Management of Infliximab Treated Patients with Psoriasis Based On Infliximab Plasma Levels and Antibodies to Infliximab, Clinical & Experimental Dermatology Research, 5(2), 2014. Department of Dermatology and Venerology, Comenius University Faculty of Medicine, Bratislava, Slovakia, |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Pallagi-Kunstár É. et al., Utility of serum TNF-a, infliximab trough level, and antibody titers in inflammatory bowel disease. World J Gastroenterol. 20(17): (5031-5035), 2014. Department of Medicine, University of Szeged, H6720 Szeged, Hungary |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Khanna R., et al., Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. Gastroenterology & Hepatology, (478-489),2014. Department of Medicine at the University of Western Ontario in London, Ontario, Canada. |
ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA |
Visit Link | |
| Krajcovicova A. et al., Delayed hypersensitivity reaction after initial dose of infliximab: a case report. European Journal of Gastroenterology& Hepatology, 26:(485-487), 2014. Gastroenterology Unit, Department of Internal Medicine V., University Hospital Bratislava, Bratislava, Slovakia. |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Erdemli Ö, et al, In vitro evaluation of effects of sustained anti-TNF release from MPEG-PCL-MPEG and PCL microspheres on human rheumatoid arthritis synoviocytes.2014. Journal of Biomaterials Application, 29(4):524-42, 2014. Department of Engineering Sciences, Middle East Technical University, Ankara, Turkey |
ETANERCEPT |
Shikari® (Q-ETA) Etanercept ELISA |
Visit Link | |
| Avdeeva A.A., Aleksandrova E.N., Karateev D.E., Luchikhina E.L., Novikov A.A., Cherkasova M.V., Nasonov E.L. Efficacy Of Adalimumab In Early Rheumatoid Arthritis In Relation To Its Serum Level And The Presence Of Anti-Drug Antibody, Rheumatology Science and Practice, 52(6):624–630, 2014. V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia |
ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (S-ATA) Anti-Adalimumab ELISA |
Visit Link | |
| Bortlik M, et al, Impact of Anti-Tumor Necrosis Factor Alpha Antibodies Administered to Pregnant Women With Inflammatory Bowel Disease on Long-term Outcome of Exposed Children. Inflamm Bowel Dis 20 : (495-451), 2014. IBD Clinical and Research Centre, ISCARE, Charles University, Prague, Czech Republic |
INFLIXIMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Jung Y et al., “Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis”, J. Control. Release 2013. Department of Biotechnology, The Catholic University of Korea, 43 Jibong-ro, Wonmi-gu, Bucheon-si, Gyeonggi-do 420-743, Republic of Korea. |
ETANERCEPT |
Shikari® (Q-ETA) Etanercept ELISA |
Visit Link | |
| Gutierrez A, et al, Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn’s disease, Gut 0:1–9, 2013 Servicio de Medicina Digestiva, Hospital General Universitario de Alicante, Alicante, Spain |
INFLIXIMAB ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (S-ATA) Anti-Adalimumab ELISA Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| Grosen A., et al, Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease, J Crohns Colitis 2013. Dept. of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Romero G., et al, Poly(Lactide-co-Glycolide) Nanoparticles, Layer by Layer Engineered for the Sustainable Delivery of AntiTNF-α. Macromol. Biosci. 13: (903–912), 2013. CIC biomaGUNE, Paseo Miramón 182 C, 20009 San Sebastian, Gipuzkoa, Spain. |
ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA |
Visit Link | |
| Cheong C, et al, Etanercept Attenuates Traumatic Brain Injury in Rats by Reducing Brain TNF-α Contents and by Stimulating Newly Formed Neurogenesis, Mediators of Inflammation, 2013; Volume 2013, Article ID 620837, 9 pages ** Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan |
ETANERCEPT |
Shikari® (Q-ETA) Etanercept ELISA |
Visit Link | |
| Bortlik M et al, “Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-a therapy during pregnancy: three-center study”, Scandinavian Journal of Gastroenterology. 48: 951–958, 2013. IBD Clinical and Research Centre, ISCARE, Charles University, Prague, Czech Republic. |
INFLIXIMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Bodini G, Savarino V, Fazio V, et al. Relationship Between Drug Serum Co ncentration and Clinical Activity in Patients With Crohn Disease Who Achieved Remission With Adalimumab – a Prospective Study,Aga, Volume 142, Issue 5, Supplement 1, Page S-388, 2012. Gastrointestinal Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy. |
ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (S-ATA) Anti-Adalimumab ELISA w/confirmation |
Visit Link | |
| Bortlik M, et al, Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease, Journal of Crohn's and Colitis, 2012. IBD Clinical and Research Centre, ISCARE a.s., 1st Faculty of Medicine, Charles University in Prague, Czech Republic |
INFLIXIMAB |
Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Malickova K, et al, Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases, Autoimmun Highlights, 2012. Laboratory of Clinical Immunology and Allergology, Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine and General University Hospital, Charles University in Prague, Karlovo na´meˇstı´ 32, 121 11 Prague 2, Czech Republic |
INFLIXIMAB |
Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Takahashi H, et al, Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis, Journal of Dermatology, 39: 1- 4, 2012. Department of Dermatology, Asahikawa Medical University, Asahikawa, Japan |
INFLIXIMAB |
Shikari® (S-ATA) Anti-Adalimumab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| Seok Lee Y, et al, “Efficacy of Early Infliximab Treatment for Pediatric Crohn’s Disease: A Three-year Follow-up”, Pediatric Gastroenterology, Hepatology & Nutrition, 15(4):243-249, 2012. Department of Pediatrics, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul |
INFLIXIMAB |
Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| Molnar T, et al, “Importance of trough levels and antibody titers on the efficacy and safety of Infliximab therapy in inflammatory bowel disease”, Z Gastroenterol, 50 - A53, 2012. First Department of Medicine, University of Szeged, Szeged, Hungary |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Kato S, et al, “Elevated Serum IgE Prior to Acute Severe Infusion Reaction During Infliximab Maintenance Therapy in a Crohn’s Disease Patient”, Crohn’s & Colitis Foundation of America, 2011. Department of Gastroenterology and Hepatology, Saitama Medical Centre, Saitama Medical University, Saitama, Japan |
INFLIXIMAB |
Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Adisen E, et al, “Anti-infliximab antibody status and its relation to clinical response in psoriatic patients”: A pilot study, Journal of Dermatology, 37: 708–713, 2010. Department of Dermatology, Gazi University, Faculty of Medicine, Ankara, Turkey. |
INFLIXIMAB |
Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| Pękala, Anna, Rafał Filip, and David Aebisher. "Anti-drug antibodies in patients with inflammatory bowel diseases treated with biosimilar infliximab: A prospective cohort study." Journal of Clinical Medicine 10.12 (2021): 2653. Department of Gastroenterology, IBD Unit of Clinical Hospital 2, Lwowska 60 Str., 35-301 Rzeszow, Poland |
INFLIXIMAB |
Shikari® (S-AIR) Anti-Infliximab biosimilar ELISA |
Visit Link | |
| Hollevoet, Kevin, et al. "Bridging the clinical gap for DNA-based antibody therapy through translational studies in sheep." Human Gene Therapy 30.11 (2019): 1431-1443.
Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, University of Leuven, Leuven, Belgium |
TRASTUZUMAB |
Shikari® (Q-TRAS) Trastuzumab ELISA |
Visit Link | |
| Sakane, Hideo, et al. "Anti-drug antibodies and rheumatoid factor level in patients with rheumatoid arthritis using the infliximab biosimilar CT-P13." BMC rheumatology 6.1 (2022): 1-5.
Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, 3-39-22, Showamachi, Maebashi, Gunma, 371-8511, Japan |
INFLIXIMAB |
Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Download | |
| Rentsch, Clarissa A., et al. "Pharmacist-Driven Therapeutic Infliximab Monitoring at the Point Of Care Using Rapidly Assessed Drug Levels In Patients with Inflammatory Bowel Disease." Therapeutic Drug Monitoring (2022): 10-1097. Department of Gastroenterology Alfred Health and Central Clinical School, Monash University. Ms. Rentsch is now with the Department of Gastroenterology, Royal Melbourne Hospital, Melbourne |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Golshani, Maryam, et al. "SARS-CoV-2 Specific Humoral Immune Responses after BNT162b2 Vaccination in Hospital Healthcare Workers." Vaccines 10.12 (2022): 2038. Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, 121 08 Prague, Czech Republic |
CORONAHUNTER® ELISA KITS |
CORONAHUNTER® (Q-CORS1) anti-S1 IgG ELISA CORONAHUNTER® (Q-CORS1IgM) anti-S1 IgM ELISA |
Download | |
| Maspero, Marianna, et al. "S79 Long Term Outcomes of Straight Ileoanal Anastomoses Converted to Ileal Pouch Anal Anastomoses." Official journal of the American College of Gastroenterology| ACG 117 (2022): S21. Department of Colon & Rectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH, USA |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Download | |
| Maffei Svobodová, Ludmila, et al. "Multidisciplinární spolupráce při výzkumu stanovení hladin protilátek IgG a IgM u onemocnění COVID 19." (2022).
Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, 121 08 Prague, Czech Republic |
CORONAHUNTER® ELISA KITS |
CORONAHUNTER® (Q-CORSRBD) anti-spike RBD IgG ELISA CORONAHUNTER® (Q-CORSRBDIgM) anti-spike RBD IgM ELISA |
Download | |
| M Zviaglova and others, P453 The significance of the concentration of antibodies to infliximab on the frequency of loss of response when alternating the original drug infliximab and its biosimilar in patients with ulcerative colitis. Moscow Clinical Scientific Center named after A. S. Loginov, Department of IBD, Moscow, Russian Federation |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Bai Y, Li W, Yan C, Hou Y, Wang Q. Anti-rituximab antibodies in patients with refractory autoimmune nodopathy with anti-neurofascin-155 antibody. Front Immunol. 2023 Mar 28;14:1121705. Department of Neurology, Qilu Hospital of Shandong University, Jinan, China. |
RITUXIMAB |
Shikari® (S-ATR) Anti-Rituximab ELISA |
Visit Link | |
| Pangua C. et al. Mucus‑penetrating and permeation enhancer albumin‑based nanoparticles for oral delivery of macromolecules: Application to bevacizumab
NANO-VAC Research Group, Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, University of Navarra, 31008, Pamplona, Spain |
BEVACIZUMAB |
Shikari® (Q-BEVA) Bevacizumab ELISA |
Visit Link | |
| Shibata H, Nishimura K, Saito Y, Ishii-Watabe A. Comparison of Immunochemical Reactions of Infliximab Innovator and Biosimilars on an Infliximab Detection Kit Used for Therapeutic Drug Monitoring. Biol Pharm Bull. 2023;46(4):621-629.
Division of Biological Chemistry and Biologicals, National Institute of Health Sciences. |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Rahman MT, Kaung Y, Shannon L, Androjna C, Sharifi N, Labhasetwar V. Nanoparticle-mediated synergistic drug combination for treating bone metastasis. J Control Release. 2023 May;357:498-510. Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA. |
DENOSUMAB |
Shikari® (Q-DEN) Denosumab ELISA |
Visit Link | |
| Nguyen AL, Gibson PR, Upton RN, Mould DR, Sparrow MP. Application of a precision-dosing model to a real-world cohort of patients on infliximab maintenance therapy: Drug usage and cost analysis. J Clin Pharmacol. 2023 Nov 15. Department of Gastroenterology, Central Clinical School, Monash University and Alfred Health, Melbourne, Victoria, Australia. |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Choi SY, Kwon Y, Choi S, Lee SM, Choe BH, Kang B. Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn's disease. Front Immunol. Department of Pediatrics, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Republic of Korea. |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Evaluation of selected serum biomarkers levels in response to the infliximab reference product (Remicade®) versus its biosimilar (Remsima®) in a sample of ulcerative colitis patients: a cross-sectional study Depatment of Clinical Pharmacy, College of Pharmacy, Uruk University, Baghdad, 10011, Iraq |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI TOTAL) Anti-Infliximab ELISA (Free/Total Ab) |
Visit Link | |
| Therapeutic Drug Monitoring of Golimumab for the Prediction of Long-Term Clinical Remission in Patients with Ulcerative Colitis
2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan. |
GOLIMUMAB |
Shikari® (Q-GOL) Golimumab ELISA Shikari® (S-ATG) Anti-Golimumab ELISA w/confirmation |
Visit Link | |
| Efficacy of tumor necrosis factor-α inhibitors in the treatment of various immunoinflammatory diseases:focus on immunogenicity/Эффективность ингибиторов фактора некроза опухоли α в лечении различных иммуновоспалительных заболеваний:фокус на иммуногенность Kazan State Medical University, Ministry of Health of Russia, Kazan |
INFLIXIMAB ADALIMUMAB ETANERCEPT |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (S-ATA) Anti-Adalimumab ELISA Shikari® (Q-CERT) Certolizumab ELISA Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| Yewei Chen, et al., Using real-world data to inform dosing strategies of rituximab for pediatric patients with frequent-relapsing or steroid-dependent nephrotic syndrome: a prospective pharmacokinetic-pharmacodynamic study Department of Pharmacy, Children’s Hospital of Fudan University, National Children’s Medical Center, Shanghai, China |
RITUXIMAB |
Shikari® (Q-RITUX) Rituximab ELISA Shikari® (S-ATR) Anti-Rituximab ELISA |
Visit Link | |
| Jessica Cusato, Therapeutic Drug Monitoring as a Tool for the Clinical Outcome Prediction in Vedolizumab-Treated Patients: An Italian Pilot Study Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin, Turin, Italy |
VEDOLIZUMAB |
Shikari® (Q-VEDO) Vedolizumab ELISA Shikari® (S-ATV) Anti-Vedolizumab ELISA w/confirmation |
Download | |
| Saleh, H. H., Khadim , D. J., & Hussein, R. J. (2024). Correlation between Therapeutic Drug Monitoring of Infliximab Serum Trough Levels and other Biomarkers in Iraqi Patients with Crohn’s Disease. Al-Rafidain Journal of Medical Sciences Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq |
INFLIXIMAB-BIOSIMILAR |
Shikari® (Q-REMS) Infliximab biosimilar ELISA Shikari® (S-AIR) Anti-Infliximab biosimilar ELISA w/confirmation |
Visit Link |
Posters
| # | Title | Products | Kits | Action |
|---|---|---|---|---|
| Choi, So Yoon, et al. "Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients." Journal of Korean Medical Science 35.17 (2020). Department of Pediatrics, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea |
ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (S-ATA) Anti-Adalimumab ELISA |
Visit Link | |
| Little, R., et al. "P709 Is there a difference in adalimumab drug levels according to pen vs. syringe use: An international, multi-centre retrospective analysis." Journal of Crohn's and Colitis 12.supplement_1 (2018): S469-S470. Alfred Health and Monash University, Gastroenterology, Melbourne, Australia, |
ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA |
Visit Link | |
| García Gil S, Ramos Díaz R., ANÁLISIS DE LA CONCENTRACIONES PLASMÁTICAS DE NIVOLUMAB EN EL TRATAMIENTO DEL CPNM Servicio de Farmacia. Complejo Hospitalario Universitario de Canarias, La Laguna (Tenerife) |
NIVOLUMAB |
Shikari® (Q-NIVO) Nivolumab ELISA |
Visit Link | |
| H. Akbulut, M. Ocal et al., The trough levels of bevacizumab significantly affects the outcome of the treatment in patents with metastatic colorectal cancer: A Turkish Oncology Group Study Medical Oncology, Ankara University School of Medicine, Ankara Oncology Hospital, School of Medicine. Ankara, TR |
BEVACIZUMAB |
Shikari® (S-ATB) Anti-Bevacizumab ELISA w/confirmation |
Visit Link | |
| Patil A, Upadhyaya SK, Dawar R, et al., Through Infiliximab Levels and Anti-Infiliximab Antibodies in Spondyloarthritis Patients on Treatment with Low Dose Infiliximab: A Single Centre Cross-Sectional Study, BMJ Journals, Annals of the Rheumatic Diseases,(2017). Rheumatology; Microbiology, Indraprastha Apollo Hospitals, Delhi, India |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Malickova K, Duricova D , Kolar M, et al., No difference in immunogenicity of the original and biosimilar infliximab in patients with inflammatory bowel disease: short-term results, First Medical Faculty and General Teaching Hospital, Charles University, Institute of Medical Biochemistry and Laboratory Diagnostics, Prague, Czech Republic, 2 ISCARE, IBD clinical and research centre, Prague, Czech Republic, (2017). Clinical and Research Center for Inflammatory Bowel Disease, ISCARE a.s, Prague, Czech Republic. |
INFLIXIMAB |
Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| H. Akbulut, et al: The role of immune system on the efficacy of bevacizumab in patients with metastatic colorectal cancer (mCRC). Annals of Oncology, Volume 27, 2016, 7–11 October 2016, Copenhagen, Denmark. Medical Oncology, Ankara University School of Medicine, Ankara, Turkey. |
BEVACIZUMAB |
Shikari® (Q-BEVA) Bevacizumab ELISA |
Visit Link | |
| Perez I, Fernandez L, Sanchez-Ramón S, P551 Comparison of 4 assay kits for measuring infliximab trough levels and antibodies to infliximab in patients with inflammatory bowel disease,Hospital Clínico San Carlos, IBD Unit, Madrid, Spain, Hospital Clínico San Carlos, Clinical Immunology, IdiSSC, IBD Unit, Gastroenterology,2016 Madrid, Spain. Hospital Clínico San Carlos, IBD Unit, Madrid, Spain |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Goldberg R., et al, Predictors of sub-therapeutic infliximab oradalimumab trough levels and anti-drug antibodies and their influence on therapeutic decisions, ECCO 2014 Inflammatory Bowel Disease. Monash University, Monash Health, Dept. of Gastroenterology, Melbourne, Australia |
INFLIXIMAB ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Julsgaard M., et al, Intra-uterine Exposure to Anti-TNF-alpha therapy (ERA study):Infliximab and adalimumab cord blood levels correlate with maternal levels at birth, ECCO 2014 Inflammatory Bowel Disease. Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark |
ADALIMUMAB |
Shikari® (S-ATA) Anti-Adalimumab ELISA w/confirmation |
Visit Link | |
| Szepes Z., et al, Clinical utility of measuring serum TNF alpha level, anti TNF alpha levels and antibody titers in critical situations in inflammatory bowel disease and in psoriasis, ECCO 2014 Inflammatory Bowel Disease. University of Szeged, First Department of Medicine, Szeged, Hungary |
INFLIXIMAB ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (S-ATA) Anti-Adalimumab ELISA Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| Julsgaard M, et al, Time since last drug exposure in pregnancy determines Adalimumab and Infliximab levels in neonates(Era Study), Italy 2014. Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark |
ADALIMUMAB |
Shikari® (S-ATA) Anti-Adalimumab ELISA w/confirmation |
Visit Link | |
| Bodini G, et al, Correlation between Adalimumab trough serum concentration, Anti-Adalimumab antibodies and TNF-Alpha levels with clinical outcome in patients affected by Crohn’s disease,. United European Gastroenterology. Italy 2013. Gastroenterology Unit, Department of Internal Medicine, IRCCS-Azienda Ospedaliera Universitaria San Martino-IST, University of Genoa, Genoa, Italy. |
ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (S-ATA) Anti-Adalimumab ELISA |
Visit Link | |
| Duricova D, et al, Predictors of sustained response to infliximab with Crohn’s disease: A single cohort study, Czech Republic 4th Department of Internal Medicine, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Lukas M, et al, Anti-infliximab antibodies in routine clinical practice is it worth to assess them, Czech Republic PIGMOD Center, Laboratory of Cell Regeneration and Plasticity, Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Libechov, Czech Republic. |
INFLIXIMAB |
Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| Malickova K, et al, Relationship between serum trough infliximab levels, serum antibodies to infliximab, serum albumin levels and clinical response to infliximab treatment in patients with inflammatory bowel diseases, Charles University in Prague Czech Republic. (2011) Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine of Charles University and General University Hospital, Prague, Czech Republic |
INFLIXIMAB |
Shikari® (S-ATA) Anti-Adalimumab ELISA w/confirmation Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Malickova K, et al, Formation of antiphospholipid antibodies and antibodies to infliximab in anti-TNF-alpha antibody-treated patients with inflammatory bowel diseases, Charles University in Prague Czech Republic (2011). Institute of Clinical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine and General University Hospital, Charles University in Prague, Czech Republic |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Malickova K, et al,. Monitoring patients treated with infliximab: Assessing Anti-Infliximab antibodies, Czech Republic. EUROMEDLAB. Autoimmune diseases 2009. S115 Institute of Clinical Biochemistry and Laboratory Diagnostics, General Teaching Hospital and 1st Faculty of Medicine of Charles University, Prague, Czech Republic |
INFLIXIMAB |
Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link |
Thesis
| # | Title | Products | Kits | Action |
|---|---|---|---|---|
| Evaluación de la relación exposición-respuesta de bevacizumab y de cetuximab en cáncer colorrectal metastásico y de cetuximab en cáncer de cabeza y cuello Silvia Peña Cabia UNIVERSIDAD COMPLUTENSE DE MADRID, Madrid, Spain |
BEVACIZUMAB CETUXIMAB |
Shikari® (Q-BEVA) Bevacizumab ELISA Shikari® (Q-CET) Cetuximab ELISA |
Visit Link | |
| TNF-α antagonist attenuates systemic lipopolysaccharide-induced brain white matter injury in neonatal rats Shin, Seung Han, M.D. National University, Seoul, Korea |
ETANERCEPT |
Shikari® (Q-ETA) Etanercept ELISA |
Visit Link | |
| A BIOLÓGIAI TERÁPIA HATÉKONYSÁGA ÉS KORLÁTAI KÜLÖNBÖZŐ TÍPUSÚ GYULLADÁSOS BÉLBETEGSÉGEKBEN Dr. Molnár Tamás Szegedi Tudományegyetem |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| A PIKKELYSÖMÖR KLINIKAI, BIOKÉMIAI, IMMUNOLÓGIAI ÉS GENETIKAI JELLEGZETESSÉGEINEK VIZSGÁLATA Dr. Gyulai Rolland Pécsi Tudományegyetem, ÁOK |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA |
Visit Link | |
| La Spectrometrıe De Masse Applıquee A La Quantıfıcatıon Absolue Des Antıcorps Monoclonaux Therapeutıques En Mılıeu Plasmatıque Pour La Realısatıon D’etudes Pharmacocınetıques Pharmacodynamıques Dr.Rachel LEGERON-LIEUTENANT Universitè de Bordeaux, France |
BEVACIZUMAB |
Shikari® (Q-BEVA) Bevacizumab ELISA |
Visit Link | |
| EVALUATION of TRANSSCLERAL PERMEABILITY EFFECTS of NANOTECHNOLOGY BASED DRUG DELIVERY SYSTEM in OCULAR DRUG APPLICATIONS Dr. NAGİHAN UĞURLU Hacettepe University |
BEVACIZUMAB |
Shikari® (Q-BEVA) Bevacizumab ELISA |
Visit Link | |
| INVESTIGATION OF THE PATHOMECHANISM OF DIARRHOEA-RELATED DISEASES Dr. ÉVA PALLAGI University of Szeged |
INFLIXIMAB |
Shikari® (Q-INFLIXI) Infliximab ELISA Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation |
Visit Link | |
| Radiomarcaje y biodistribución mediante SPECT-CT de nanopartículas de seroalbúmina humana con bevacizumab Dr. ROCÍO RAMOS MEMBRIVE Universidad de Navarra |
BEVACIZUMAB |
Shikari® (Q-BEVA) Bevacizumab ELISA |
Visit Link | |
| ASOCIACIÓN ENTRE EL PERFIL DE CITOCINAS PRO- INFLAMATORIAS, LOS EVENTOS INMUNOGÉNICOS Y LA ACTIVIDAD CLÍNICA EN PACIENTES CON ARTRITIS REUMATOIDE TRATADOS CON INFLIXIMAB Y ADALIMUMAB Q.F.B. EMMANUEL ANTONIO ORTIZ SALDIVAR UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MORELOS |
ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (S-ATA) Anti-Adalimumab ELISA |
Visit Link | |
| Nanoparticle and Macromolecular Transfer across the Human Placental Barrier Michael Gruber MSc. BSc. |
TRASTUZUMAB DENOSUMAB |
Shikari® (Q-DEN) Denosumab ELISA Shikari® (Q-TRAS) Trastuzumab ELISA |
Download | |
| CRUCIAL STEPS FOR TREATMENT OPTIMIZATION AND DECISION MAKING IN INFLAMMATORY BOWEL DISEASE MANAGEMENT. Szántó, Kata Judit |
INFLIXIMAB ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| K.T. Bildik, Investigation of cellular and humoral immune responses induced by SARS-CoV-2 VLP vaccine in Pre-clinical and clinical studies, 2022 Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey |
CORONAHUNTER® ELISA KITS |
CORONAHUNTER® (Q-CORS-IGG) anti-Spike Trimer IgG ELISA |
Visit Link | |
Wu, Yang, Therapeutic drug monitoring to optimise treatment of inflammatory bowel disease with tumour necrosis factor inhibitorsUniversity of New South Wales, Sydney, Australia |
INFLIXIMAB ADALIMUMAB |
Shikari® (Q-ADA) Adalimumab ELISA Shikari® (Q-INFLIXI) Infliximab ELISA |
Visit Link | |
| Büşra AKAY HACAN, RUTİN TEDAVİ OLARAK BEVACİZUMAB KULLANILAN METASTATİK KOLOREKTAL KANSERLİ HASTALARDA TEDAVİ ETKİNLİĞİNİN BELİRLENMESİNDE BİYOBELİRTEÇLERİN ROLÜ ANKARA ÜNİVERSİTESİ TIP FAKÜLTESİ, TÜRKİYE CUMHURİYETİ |
BEVACIZUMAB |
Shikari® (Q-BEVA) Bevacizumab ELISA |
Visit Link |
Patents
| # | Title | Products | Kits | Action |
|---|---|---|---|---|
| Imaging probe for angiogenic activity in pulmonary arterial hypertension Paul B. YuMarcelo DICARLI THE BRIGHAM AND WOMEN'S HOSPITAL, INC. MASSACHUSETTS, USA |
BEVACIZUMAB |
Shikari® (Q-BEVA) Bevacizumab ELISA |
Visit Link | |
| CONTROLED DRUG DELIVERY SYSTEMS FOR ANTI-TNF-α Aysen TEZCANER Dilek Keskin Seza OZEN Bulent ATILLA Ali USANMAZ Cetin KOCAEFE Ozge ERDEMLI METU DEPARTMENT OF ENGINEERING SCIENCES, ANKARA |
ETANERCEPT |
Shikari® (Q-ETA) Etanercept ELISA |
Visit Link | |
| The plant source recombinant humanized shellfish of a kind of optimization cuts down preparation method and the medical applications of monoclonal antibody, 于为常陈磊 CHINA |
BEVACIZUMAB |
Shikari® (Q-BEVA) Bevacizumab ELISA |
Visit Link | |
| Genetically modified micro-organ secreting antibody and methods of use Reem MiariNir ShapirInbal ZAFIR-LAVIE MEDGENETICS MEDICAL ISRAEL LTD., Misgav, Israel |
TRASTUZUMAB |
Shikari® (Q-TRAS) Trastuzumab ELISA |
Visit Link | |
| METHOD FOR QUANTIFYING MONOCLONAL ANTIBODY HAVIN ANTIGEN OR ANTI - ANTIBODY BONDED THERETO, Iwamoto et al. Shimadzu Corporation , Kyoto, Japan |
TRASTUZUMAB |
Shikari® (Q-TRAS) Trastuzumab ELISA |
Visit Link | |
| Formulations of biological polymers for oral administration. Rademaker BERNADRUS, MINNAARD Willem Adriaan, VAN ZWIETEN Eduard Johannes, WIELING Jacob BIORALIX B.V. Verlaat 1,8428 RS Fochteloo, Netherlands. |
OMALIZUMAB |
Shikari® (Q-OMA) Omalizumab ELISA |
Visit Link |